What can we do to Prevent Infections in Adult Patients with Rheumatic Diseases?

Richi, Patricia; Fernández, Santiago Muñoz

doi:10.4172/2471-9544.100113

J Vasc

2016

DOI: 10.4172/2471-9544.100113

|View full text |Cite

What can we do to Prevent Infections in Adult Patients with Rheumatic Diseases?

Patricia Richi¹,

Santiago Muñoz Fernández²

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 34 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunomediated inflammatory diseases (IMIDs) and biologic or targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs, respectively) are recognized factors that increase risk of infections. 1 Therefore, it was reasonable to predict at the beginning of the pandemic that IMIDs or their treatments could be risk factors for COVID-19. However, a few drugs with influence on the immune system have been used to treat COVID-19 such antimalarials, interleukin 6 inhibitors, anakinra, and baricitinib.…”

mentioning

confidence: 99%

Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs—Findings From the BIOCOVID Study

et al. 2021

View full text Add to dashboard Cite

The aim of this study was to examine the incidence of coronavirus disease 2019 (COVID-19) among patients with immunomediated inflammatory diseases (IMIDs) treated with biologic or targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) and to evaluate the influence of either IMIDs or related therapies on the incidence and evolution of COVID-19.Methods: This observational, cross-sectional study was conducted from January 31, 2020, to May 15, 2020. Data of 902 patients were obtained from clinical records in hospitals, primary care units, and community pharmacies. Inclusion criteria were adults with IMIDs treated with bDMARDs or tsDMARDs who started therapy 3 months prior to study commencement. Patients with poor adherence to treatments were excluded. COVID-19 was classified as "definitive" (severe acute respiratory syndrome coronavirus 2 polymerase chain reaction [PCR]-positive), "possible" (characteristic symptoms and negative PCR), and "suspected" (characteristic symptoms but PCR not performed).Results: COVID-19 was diagnosed in 70 patients (11 definitive, 19 possible, and 40 suspected). The cumulative incidence of definitive COVID-19 was 1.2%. When considering all cases, the incidence was 7.8%. Patients on biosimilars tumor necrosis factor blockers were more likely to have a diagnosis of COVID-19 (odds ratio, 2.308; p < 0.001). Patients on anti-B-cell therapies had a lower incidence of infections (p = 0.046). Low rates of hospitalization (14.3%), pneumonia (14.3%), death (2.9%), or thrombosis (2.9%) were observed, and 94.3% of patients recovered. Conclusions:The cumulative incidence of confirmed cases of COVID-19 was similar to the general population, with generally low hospitalization, intensive care management, and mortality rates. COVID-19 incidence was less frequent in patients with more severe immunosuppression.

show abstract

mentioning

confidence: 99%

Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs—Findings From the BIOCOVID Study

et al. 2021

View full text Add to dashboard Cite

show abstract

Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases

Romero-Bogado,

Steiner,

Vasallo

et al. 2024

Medicina Clínica (English Edition)

View full text Add to dashboard Cite

Impacto de las terapias sistémicas en la seroprevalencia de anticuerpos contra el SARS-CoV-2 en pacientes con enfermedades inmunomediadas

Romero-Bogado,

Steiner,

Thuissard Vasallo

et al. 2024

Medicina Clínica

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

What can we do to Prevent Infections in Adult Patients with Rheumatic Diseases?

Cited by 3 publications

References 34 publications

Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs—Findings From the BIOCOVID Study

Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs—Findings From the BIOCOVID Study

Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases

Impacto de las terapias sistémicas en la seroprevalencia de anticuerpos contra el SARS-CoV-2 en pacientes con enfermedades inmunomediadas

Contact Info

Product

Resources

About